Form 8-K - Current report:
SEC Accession No. 0001104659-25-055100
Filing Date
2025-06-02
Accepted
2025-06-02 06:02:21
Documents
15
Period of Report
2025-05-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2516518d1_8k.htm   iXBRL 8-K 28907
2 EXHIBIT 2.1 tm2516518d1_ex2-1.htm EX-2.1 53610
3 EXHIBIT 99.1 tm2516518d1_ex99-1.htm EX-99.1 17851
7 GRAPHIC tm2516518d1_ex99-1img001.jpg GRAPHIC 17318
  Complete submission text file 0001104659-25-055100.txt   311424

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA tbph-20250530.xsd EX-101.SCH 3020
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tbph-20250530_lab.xml EX-101.LAB 34239
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tbph-20250530_pre.xml EX-101.PRE 22362
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2516518d1_8k_htm.xml XML 3704
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 251012989
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)